ES2807878T3 - Uso de la modulación de H3K9me3 para potenciar la función cognitiva - Google Patents

Uso de la modulación de H3K9me3 para potenciar la función cognitiva Download PDF

Info

Publication number
ES2807878T3
ES2807878T3 ES16808065T ES16808065T ES2807878T3 ES 2807878 T3 ES2807878 T3 ES 2807878T3 ES 16808065 T ES16808065 T ES 16808065T ES 16808065 T ES16808065 T ES 16808065T ES 2807878 T3 ES2807878 T3 ES 2807878T3
Authority
ES
Spain
Prior art keywords
etp69
compound
cognitive
h3k9me3
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16808065T
Other languages
English (en)
Spanish (es)
Inventor
Carl Cotman
Larry Overman
Shikha Snigdha
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Application granted granted Critical
Publication of ES2807878T3 publication Critical patent/ES2807878T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/548—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Networks Using Active Elements (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Amplifiers (AREA)
ES16808065T 2015-06-08 2016-06-03 Uso de la modulación de H3K9me3 para potenciar la función cognitiva Active ES2807878T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562172690P 2015-06-08 2015-06-08
PCT/US2016/035764 WO2016200690A1 (en) 2015-06-08 2016-06-03 USE OF H3K9me3 MODULATION FOR ENHANCING COGNITIVE FUNCTION

Publications (1)

Publication Number Publication Date
ES2807878T3 true ES2807878T3 (es) 2021-02-24

Family

ID=57504356

Family Applications (2)

Application Number Title Priority Date Filing Date
ES16808065T Active ES2807878T3 (es) 2015-06-08 2016-06-03 Uso de la modulación de H3K9me3 para potenciar la función cognitiva
ES20172824T Active ES2944446T3 (es) 2015-06-08 2016-06-03 Uso de la modulación de H3K9me3 para potenciar la función cognitiva

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES20172824T Active ES2944446T3 (es) 2015-06-08 2016-06-03 Uso de la modulación de H3K9me3 para potenciar la función cognitiva

Country Status (11)

Country Link
US (5) US10272093B2 (enExample)
EP (2) EP3733188B1 (enExample)
JP (1) JP6851081B2 (enExample)
KR (1) KR102776570B1 (enExample)
CN (1) CN107849061B (enExample)
AU (2) AU2016276172B2 (enExample)
CA (1) CA2988568A1 (enExample)
ES (2) ES2807878T3 (enExample)
IL (1) IL256055B (enExample)
MX (1) MX2017015909A (enExample)
WO (1) WO2016200690A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3733188B1 (en) * 2015-06-08 2023-01-25 The Regents of the University of California Use of h3k9me3 modulation for enhancing cognitive function
JP2020524157A (ja) * 2017-06-20 2020-08-13 アンスティテュート キュリー がん併用療法における使用のためのｓｕｖ３９ｈ１ヒストンメチルトランスフェラーゼの阻害剤
CN108434454B (zh) * 2018-03-16 2019-10-11 大连医科大学 Adar1在缓解认知功能障碍方面的应用
US20220313782A1 (en) * 2019-05-02 2022-10-06 Board Of Regents, The University Of Texas System Methods and compositions involving tert activating therapies
US20240009203A1 (en) * 2020-08-03 2024-01-11 Cedars-Sinai Medical Center Compositions and methods for treating alzheimer's disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534255B1 (en) 2003-01-24 2009-05-19 Photothera, Inc Low level light therapy for enhancement of neurologic function
US20060019227A1 (en) 2004-07-22 2006-01-26 Hardwicke Susan B Methods for cognitive treatment
CA2601777A1 (en) 2005-02-03 2006-08-10 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
WO2007146073A2 (en) * 2006-06-09 2007-12-21 Wyeth Method for enhancing cognitive function
JP2009084271A (ja) * 2007-09-07 2009-04-23 Toyama Univ 脳由来神経栄養因子の発現誘導剤および発現誘導方法
NZ593447A (en) * 2008-12-03 2012-12-21 Harvard College Inhibition of hdac2 to promote memory
US8969364B2 (en) * 2010-03-04 2015-03-03 Merck Sharp & Dohme Corp. Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders
KR101235256B1 (ko) * 2010-09-13 2013-02-21 서울대학교산학협력단 ｍｉＲＮＡ를 타겟으로 한 신경퇴행성 질환 치료
CN108440571B (zh) * 2012-10-22 2022-11-04 希望之城 Etp衍生物
CA2909506C (en) * 2013-04-17 2021-04-20 H. Lundbeck A/S Nalmefene for treatment of patients with anxiety disorder
AU2014354808A1 (en) * 2013-11-26 2016-06-02 University Of North Texas Health Science Center At Fort Worth Personalized medicine approach for treating cognitive loss
EP3733188B1 (en) * 2015-06-08 2023-01-25 The Regents of the University of California Use of h3k9me3 modulation for enhancing cognitive function

Also Published As

Publication number Publication date
KR20180014432A (ko) 2018-02-08
AU2019246902B2 (en) 2021-08-19
US11311551B2 (en) 2022-04-26
KR102776570B1 (ko) 2025-03-04
US20190209577A1 (en) 2019-07-11
JP6851081B2 (ja) 2021-03-31
US20180228808A1 (en) 2018-08-16
US20230057592A1 (en) 2023-02-23
EP3733188A1 (en) 2020-11-04
US10272093B2 (en) 2019-04-30
US10849910B2 (en) 2020-12-01
US20210106590A1 (en) 2021-04-15
EP3303347A1 (en) 2018-04-11
EP3733188B1 (en) 2023-01-25
AU2019246902A1 (en) 2019-10-31
IL256055A (en) 2018-01-31
CA2988568A1 (en) 2016-12-15
JP2018516940A (ja) 2018-06-28
US20240374608A1 (en) 2024-11-14
WO2016200690A1 (en) 2016-12-15
ES2944446T3 (es) 2023-06-21
IL256055B (en) 2022-06-01
MX2017015909A (es) 2018-05-07
CN107849061B (zh) 2021-05-14
EP3303347A4 (en) 2019-03-06
AU2016276172B2 (en) 2019-07-11
CN107849061A (zh) 2018-03-27
AU2016276172A1 (en) 2018-01-04
EP3303347B1 (en) 2020-05-06

Similar Documents

Publication Publication Date Title
Song et al. Cardiolipin remodeling by ALCAT1 links mitochondrial dysfunction to Parkinson’s diseases
ES2807878T3 (es) Uso de la modulación de H3K9me3 para potenciar la función cognitiva
Večeřa et al. HDAC1 and HDAC3 underlie dynamic H3K9 acetylation during embryonic neurogenesis and in schizophrenia‐like animals
Choi et al. Effect of exercise-induced neurogenesis on cognitive function deficit in a rat model of vascular dementia
Costa et al. Electrophysiology and pharmacology of striatal neuronal dysfunction induced by mitochondrial complex I inhibition
Niu et al. Endogenous sulfur dioxide regulates hippocampal neuron apoptosis in developing epileptic rats and is associated with the PERK signaling pathway
Ma et al. A novel phthalein component ameliorates neuroinflammation and cognitive dysfunction by suppressing the CXCL12/CXCR4 axis in rats with vascular dementia
Li et al. Inhibition of Cdk5 rejuvenates inhibitory circuits and restores experience-dependent plasticity in adult visual cortex
ES2827194T3 (es) Moduladores de la concentración de cloruro intracelular para el tratamiento del síndrome del X frágil
Carreón-Trujillo et al. No effects of Decanoic acid on locomotor activity and antioxidant Defences in an experimental animal model of attention-deficit/hyperactivity disorder
HK40040355B (en) Use of h3k9me3 modulation for enhancing cognitive function
HK40040355A (en) Use of h3k9me3 modulation for enhancing cognitive function
Kong et al. Research Progress on the Biological Function and Homeostatic Disruption of Microglia in the Pathogenesis of Major Depressive Disorder
Zhang A Neural Pathway Underlying 14-3-3 Dysfunction-Induced Psychomotor Behavior
Shelton The Effects of Two Novel Anti-Inflammatory Compounds on Prepulse Inhibition and Neural Microglia Cell Activation in a Rodent Model of Schizophrenia
Zhao et al. Ganoderma lucidum spore powder modulates Bcl-2 and Bax expression in the hippocampus and cerebral cortex, and improves learning and memory in pentylenetetrazole-kindled rats**★
Chao-Liang et al. Tongqiao Huoxue Decoction ameliorates learning and memory defects in rats with vascular dementia by up-regulating the Ca2+-CaMKII-CREB pathway
Abdulla Investigating neuroprotectants for the treatment of Chemotherapy-Induced Peripheral Neuropathy
Soman DOCTOR OF PHILOSOPHY IN BIOTECHNOLOGY
Singh et al. Thioredoxin-Mimetic Peptide (Cb3) Exhibits Antiepileptogenic Effects and Modifies Chronic Epilepsy in a Temporal Lobe Epilepsy Model
Campbell The role of calcineurin in dendritic remodeling and epileptogenesis in a rat model of traumatic brain injury
Carlos et al. IMR Press
IT201800005062A1 (it) Modulatori dell’attività di segnale dell’indolamina 2,3-diossigenasi e loro impieghi terapeutici.
Singh TRANQUILIZING AGENTS, BIBLIOGRAPHY